CD47 and lymphoma: Of note, it has been recently reported that administration of chemotherapy before, but not after, CD47 blocking antibodies resulted in synergistic tumour control in a mouse lymphoma model, as explained in the paper, chemotherapy may synergize with anti-CD47 by increasing release of antigens and DNA from dying tumor cells; contrarily, chemotherapy administered after anti-CD47 therapy had detrimental effects on development of beneficial antitumor memory immune responses [23].